Home Featured, Press Release

Blacklisting of Aveo Pharmaceuticals and Banning of Tapentadol and Carisoprodol Combination – Tafrodol or Royal 225

Drug Spotlight, Drugs Programmes, Home Featured

Implementation of ICH Q1 and Q7 Guidelines

Home Featured, Press Release

Emergency use authorization of the Mpox vaccine by NAFDAC: A crucial step in Nigeria’s public health response

Home Featured

NAFDAC Traceability: Find out all you need to know here

Home Featured, Vaccine Publications

Vaccine Types And Benefits: What You Need To Know

Home Featured, Press Release

Approval by NAFDAC on use of Gardasil Vaccine as Single Dose in the Routine Immunization

Gardasil is a vaccine that protects against human papillomavirus (HPV), a common sexually transmitted infection that can cause cervical, vaginal, vulvar, and other cancers.

Products We Regulate

e-Services

NAFDAC Updates

Press Release

March 14, 2025

Investigation Report of Scamming of Foreign Companies Using Fake NAFDAC Documents by Mr. Ikoro Mang Ifendua: A

Blacklisting of Aveo Pharmaceuticals and Banning of Tapentadol and Carisoprodol Combination – Tafrodol or Royal 225

Home FeaturedPress Release

February 28, 2025

Blacklisting of Aveo Pharmaceuticals and Banning of Tapentadol and Carisoprodol Combination – Tafrodol or Royal 225

Press Release

January 9, 2025

The Year 2025 – NAFDAC Director General’s Strategic Plan

Edit Content

March 14, 2025

Investigation Report of Scamming of Foreign Companies Using Fake NAFDAC Documents by Mr. Ikoro Mang Ifendua: A Case of

February 28, 2025

Blacklisting of Aveo Pharmaceuticals and Banning of Tapentadol and Carisoprodol Combination – Tafrodol or Royal 225

January 9, 2025

The Year 2025 – NAFDAC Director General’s Strategic Plan

December 17, 2024

NAFDAC Refutes Claims of Approving Herbal Tea Promoting Smoking

Edit Content

November 22, 2024

Opening Remarks by Prof. Mojisola Christianah Adeyeye, at the World

August 12, 2024

Remarks and Talking Points of Prof. Mojisola Christianah Adeyeye Phd,

May 20, 2024

Keynote Address by Prof. Mojisola Christianah Adeyeye at the National

February 1, 2024

Opening Remarks by Prof. Mojisola Christianah Adeyeye During the Stakeholders’

Edit Content

July 26, 2024

Unlocking the healthcare value chain: 2nd regional workshop on manufacturing Active Pharmaceutical Ingredients and excipients in Nigeria

July 20, 2024

Regional Workshop on ICH Q1 – Stability Guideline (22nd – 24th July, 2024)

September 29, 2023

Sustainable Healthcare Development: Workshop on Local Manufacturing of APIs and Excipients

February 8, 2023

Stakeholders Meeting on Implementation of Pharmaceutical Traceability & Other Pertinent Issues

Edit Content

Traceability for Strengthening Supply Chain Systems and Enhancing Real-Time Visibility: Focus of NAFDAC on Advancing Vaccines Traceability in Nigeria. Ann. Acad. Med. Siles. (2024);78:276-281
Adeyeye, Mojisola, John Kayode, and Sabitu Olasupo.
The safety, quality evaluation, and lot release of COVID‑19 vaccines imported and used in Nigeria from march 2021 to march 2022. Discover Health Systems. (2024) 3:15. N. M. Kanu, C. M. Adeyeye, V. O. Abiola, O. Adekunle–Segun, E. M. Adegoke, A. Akapo, M. A. Okezue.
Impact of Digitalization in strengthening the regulatory functions of NAFDAC: Opportunities and Challenges for other National Regulatory Authorities. Journal of Regulatory Science, 12(1). Adeyeye, M., Olasupo S., Akinyemi, A., Kayode, J., & Sonny-Afoekelu, U (2024). Partly funded by Internally Generated Revenue, Global Fund, BMGF, WHO& USAID
The safety, quality evaluation, and lot release of COVID-19 vaccines imported and used in Nigeria from march 2021 to march 2022. Discover Health Systems, 3(1), 15. Kanu, N. M., Adeyeye, C. M., Abiola, V. O., Adekunle–Segun, O., Adegoke, E. M., Akapo, A., & Okezue, M. A. (2024). Funded by Internally Generated Revenue
Trends in Adverse Event Reporting Before and After the Introduction of the Med Safety App in Nigeria. Pharmaceutical Medicine, 1-9. Elemuwa, U. G., Bitrus, F., Oreagba, I. A., Osakwe, A. I., Abiodun, A. S., Onu, K., … & Adeyeye, C. M. (2024).
Enabling Pharmaceutical Traceability in The Nigerian Supply Chain using GS1 Global Standards: Lean Traceability Including In-Country Serialization of COVID-19 Vaccines. Journal of Regulatory Science, 11(1), 1-14. Adeyeye, M., Kayode, J., Adeniran, A., Osho, F., & Udokwelu, W. (2023). Partly funded by Internally Generated Revenue, Global Fund, BMGF, WHO& USAID
Investigating Using R, s, and x Charts in Monitoring Performance of Laboratory Equipment. The Proceedings of the BIRS Community, 1(1), 6. Okezue, M., Ebonine, S., Naluyima, A., Akobundu, E., Boogere-Wakaalo, W., Olayonu, L., … & Clase, K. (2023). Funded by Internally Generated Revenue
Secondary Validation of a Liquid Scintillation Counter-method for Residues of Tetracyclines, Beta-lactams, and Sulfonamides in Seafood/Aquaculture Products. Journal of Food Protection, 86(4), 100055. Aderibigbe, O. O., Adamu, B. B., Osaji, I. O., Babarinde, A. O., Nwachukwu, C. U., Adegboye, A., … & Adeyeye, M. C. (2023). Funded by Internally Generated Revenue
Impact of ISO/IEC 17025 laboratory accreditation in sub-Saharan Africa: a case study. BMC health services research, 20, 1-9. Okezue, M. A., Adeyeye, M. C., Byrn, S. J., Abiola, V. O., & Clase, K. L. (2020). Funded by Internally Generated Revenue

Recalls, Safety Alerts, & Blacklisting

These are recalls, safety alerts, and blacklists released by NAFDAC. The alert notices and safety communications contain safety measures to be taken and information that may impact both treatment and diagnostic choices for healthcare providers and patients. Blacklisting involves prohibiting companies from the sale, distribution, or use of their products due to safety concerns, regulatory violations, or unethical practices.

March 20, 2025

Public Alert No. 07/2025 – Alert on Falsified OXYCONTIN 80mg identified in the

March 11, 2025

Public Alert No. 06/2025 – Alert on the Sale of Counterfeit Noristerat Injection

March 11, 2025

Public Alert No. 05/2025 – Alert on the Circulation of Falsified Cikatem (Artemether

Our Services

Edit Content

Meet the Director General.

Prof Moji Adeyeye is the Director General of National Agency for Food and Drug Administration and Control (NAFDAC) where she has added strong governance structure, regulatory system strengthening, and strengthening of the local pharmaceutical companies through international best practices with emphasis on local manufacturing.

Prof. Moji Christianah Adeyeye

Director General, NAFDAC

Products We Regulate

e-Services

NAFDAC Updates

Recalls, Safety Alerts, & Blacklisting

Our Services

Meet the Director General.

Prof. Moji Christianah Adeyeye

About NAFDAC

Useful Links

NATIONAL AGENCY FOR FOOD AND DRUG ADMINISTRATION AND CONTROL (NAFDAC)

Contact us

For enquires

For complaints

Subscribe to Our Newsletter

Products We Regulate

For Industry

For Consumers

About Nafdac

Useful Links